Study Objectives: To assess whether biopsy of the labial minor salivary glands safely detects phosphorylated α-synuclein (pAS) deposits in idiopathic rapid eye movement sleep behavior disorder (IRBD), a condition that precedes the cardinal manifestations of synuclein disorders associated with Lewy-type pathology, namely, Parkinson's disease (PD) and dementia with Lewy bodies (DLB).
Introduction
Most patients with idiopathic rapid eye movement sleep behavior disorder (IRBD) are eventually diagnosed with Parkinson's disease (PD) and dementia with Lewy bodies (DLB) [1] [2] [3] , two conditions characterized by deposits of abnormal phosphorylated α-synuclein (pAS) in the central and peripheral nervous systems [4] [5] [6] . Identification of pAS in living patients with IRBD provides histopathological confirmation that this sleep abnormality represents a synucleinopathy, and this, combined with longitudinal data, may help for selecting participants for future clinical neuroprotective trials.
Biopsies of the colon, submandibular gland, and skin can detect aggregates of pAS in living participants with IRBD [7] [8] [9] [10] . It is uncertain, however, which is the optimal peripheral body site for screening α-synuclein pathology in IRBD because these procedures have shown different rates of obtaining adequate tissue for examination, different rates of sensitivity to detect pAS once sufficient tissue is obtained, and different safety [7] [8] [9] [10] . Thus, it is necessary to identify accessible organs for biopsy where the procedure is safe and able to obtain high rates of adequate tissue to be analyzed, plus high pAS positivity.
The minor salivary glands located in the inner side of the lower lip are organs accessible for biopsy [11] . This biopsy is a simple and safe procedure commonly used for the diagnosis of Sjögren syndrome and amyloidosis [11] that can identify pAS accumulation in patients with manifested PD [12] [13] [14] [15] . In the present study, we evaluated the utility and safety of the labial minor salivary glands biopsy to detect pAS deposits in participants with IRBD, and also in patients with clinically manifested PD and DLB who were previously diagnosed with IRBD.
Participants and Methods

Participants
The study was prospectively conducted between December 2015 and December 2016 at the Hospital Clinic de Barcelona, Barcelona, Spain. During this period, all consecutive patients with polysomnography-confirmed IRBD attending routine clinical visits in our sleep center were invited to undergo labial minor salivary glands biopsy. Patients with manifested PD [16] and DLB [17] who were initially diagnosed with IRBD in our sleep center and underwent routine clinical visits during the study period were also invited to undergo the biopsy. Salivary gland biopsies were also performed in controls without parkinsonism and cognitive complaints. Controls were healthy participants and individuals attending our sleep center who had sleep disorders not associated with the development of a neurodegenerative disease (e.g. obstructive sleep apnea) and in whom video-polysomnography excluded the occurrence of RBD.
On the day of biopsy, all participants underwent clinical history and neurological examination that included the motor part of the Movement Disorders Society Unified Parkinson Disease Rating scale (MDS-UPDRS-III) [18] . Constipation [19] and depression [20] were assessed by clinical interview in the IRBD group. We also reviewed the clinical charts of the patients with IRBD and noted the results of smell testing (assessed by the Spanishversion of UPSIT-40) [21] and the echogenic size of the substantia nigra (measured by transcranial sonography), performed previously to the study visit, given that these variables do not change with time in IRBD [22, 23] .
Exclusion criteria for all participants were disorders affecting the salivary glands, coagulation disorders, use of anticoagulant therapy, chemotherapy treatment, and allergy to lidocaine or epinephrine.
If the biopsy showed that one of some control participants had pAS aggregates, we assessed in them the presence of markers associated with prodromal PD: lifestyle risk factors [24] , RBD by video-polysomnography [25] , hyposmia by UPSIT-40 [21] , constipation and depression by accepted criteria [19, 20] , erectile or urine dysfunction by clinical history, excessive daytime sleepiness by Epworth Sleepiness Scale [26] , orthostatic hypotension [27] , cognitive dysfunction by the Mini-Mental State Examination [28] , and striatal dopamine transporter uptake by 123 I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl)
nortropane dopamine transporter single-photon emission computed tomography ( 123 I-FP-CIT DAT-SPECT) [29] . In those controls with pAS, we calculated the likelihood ratio for prodromal PD, according to MDS research criteria [30] .
The ethical committee at our institution approved the study and all participants gave written informed consent.
Minor salivary gland biopsy
Salivary gland specimens were obtained from normal appearing mucosa in the inner side of the lower lip [11] . After local asepsis, the lower lip was everted manually and local anesthetic infiltration (2% lidocaine with epinephrine at 1:100,000 dilution) was injected into the inner side of the lower lip. Local massage was performed to distribute the anesthetic during 5 min, and then a vertical incision of 1 to 1.5 cm was performed through the mucosa between the midline and the commissure, with a No. 15 blade scalpel. Minor salivary glands were gently pulled out from the surrounding tissue with the help of a mosquito forceps and scissors (Figures 1 and  2 ). Glands were removed with sterile tweezers and introduced into saline solution. Then the mucosal wound was sutured with 3 to 5 interrupted 4/0 absorbable sutures. The whole procedure took about 15 min, and surgeons (I.V. and C.M.) were blinded to clinical status of the participants. We assessed the occurrence and type of adverse events related to the biopsy by contacting each participant by telephone the day after the procedure and 1 week later.
α-Synuclein immunohistochemistry
Glands were immersed in 4.5% buffered formaldehyde solution for 24 hr and were embedded in paraffin [8] . Serial 5-μm thick sections starting from the beginning of the tissue block until its end were performed in all cases, and 3-18 sections were placed on each glass slide. Each section was numbered accordingly. Hematoxylin-eoxin staining was performed on the first, middle, and last sections, and immunohistochemistry for pAS (antiserine 129-pAS, clone pSyn#64; Wako, Pure Chemical Industries, Osaka, Japan; dilution 1/1000; antigen retrieval: 98% formic acid for 5 min) was performed on the corresponding adjacent section ( Figure 3A ). Positive immunoreactivity was considered when the pattern followed either small perivascular or periglandular nerve fibers. Immunostained sections were assessed blindly to the clinical diagnosis, independently by two of the authors (S.B. and E.G.). Results were then confronted in a joint discussion at a multiheader microscope. Biopsy was classified as pAS positive when at least one of the glands showed pAS immunoreactivity. All negative cases were reimmunostained for pAS to increase the number of stained sections. We additionally performed immunohistochemistry in all samples applying a second anti-α-synuclein antibody (α-synuclein 5G4, 1:4000, Roboscreen, Leipzig, Germany, mouse monoclonal) that is considered to be conformation dependent and capable to detect abnormally folded/oligomeric α-synuclein and not the physiological monomer [31] . To confirm the intra-axonal distribution of pAS immunoreactivity, we performed double immunofluorescence labeling with antibodies directed against PGP 9.5 (protein G product, 1:1000, DAKO, Glostrup, Denmark, rabbit polyclonal) and pAS (Wako). Sections were incubated with Alexa Fluor 488 or Cys3 coupled secondary antibodies (Molecular Probes, USA), and 4',6'-diamidin-2-phenylindol (DAPI) was used for nuclear visualization.
The number of positive glands of the total glands taken from each participant was counted. To assess the overall preservation of autonomic nerve fibers, antityrosine-hydroxylase (TH, clone TH-16, Sigma Aldrich, St. Louis, MO, USA, mouse monoclonal) antibody was applied. We performed a three tired, semiquantitative assessment of the density of TH-positive fibers within the whole gland and categorized it as "few," "moderate," and "abundant."
Negative control of immunostaining consisted in the omission of the primary antibody, and brain tissue of a postmortem-confirmed case of PD was used as positive control for α-synuclein and a sympathetic paravertebral ganglion for the tyrosine-hydroxylase antibody.
In the patients with IRBD who underwent labial minor salivary gland biopsy, we evaluated the presence of pAS in the submandibular gland and in the colon in those participants who underwent submandibular gland and colonic biopsies in the context of our previous studies [7, 8] . Latencies between the three different procedures in the colon, submandibular gland, and minor salivary glands were calculated.
After the biopsy, patients were followed-up clinically and in February 2018 we investigated how many participants with IRBD remained idiopathic and how many were diagnosed with PD, DLB, or other neurological condition. Their clinical status in February 2018 was compared with the presence or absence of pAS in the salivary glands. 
Statistical analysis
Results
Participants
Demographic and clinical characteristics of the participants and differences between groups are summarized in Table 1 .
Of the 96 patients with IRBD who underwent routine visits at our sleep center during the study period, 62 agreed to participate, 28 declined, and eight were excluded because of receiving anticoagulant (n = 6) or chemotherapy treatment (n = 2). The 62 patients with IRBD included in the study were 49 (79%) men and 13 (21%) women with a mean age of 72.2 ± 6.9 (range, 56 to 88) years, and a mean follow-up duration of 5.3 ± 4.0 (range, 0 to 14.4) years from IRBD diagnosis to biopsy.
Of the 21 patients with PD that underwent clinical visits during the study period, 13 consented to participate, four declined, three were excluded because of anticoagulant therapy, and one because of Sjögren syndrome. In the 13 participating patients with PD, the time between PD diagnosis and biopsy was 3.7 ± 3.9 years.
Among 19 patients with DLB that underwent clinical visits during the study period, ten agreed to participate, two declined, and seven were excluded because of anticoagulant therapy. In the 10 patients with DLB included in the study, the interval between DLB diagnosis and biopsy was 2.6 ± 1.8 years.
Thirty-three controls participated in the study. Fifteen controls were healthy individuals who were nonblood relatives and friends of the patients included in the present study. The remaining 18 controls were participants attending routine visits at our sleep center during the study period who had sleep disorders not related to the synucleinopathies; eight had obstructive sleep apnea, nine restless legs syndrome, and one propriospinal myoclonus.
Phosphorylated α-synuclein accumulation
Adequate biopsy material containing minor salivary glands for histological evaluation was available in all participants (Figure 3 , A-C). A mean of 5.5 ± 1.3 (range, 2 to 9) glands were obtained from each participant. Abnormal aggregates of pAS were detected in 31 of 62 (50%) IRBD, 7 of 13 (53.8%) PD, 5 of 10 (50%) DLB, and in 1 of 33 (3%) controls. 62.5% of the positive cases using the anti-serine 129-pAS antibody were also positive by using the conformation-dependent 5G4 antibody. Only one patient with IRBD was positive with 5G4 and negative for pAS. In the positive pAS cases, the mean number of glands containing pAS accumulation was 2.3 ± 1.14 (range, 1 to 5), and the mean percentage of glands containing pAS deposits was 42.4 ± 23.4 (range, 12.5 to 100). Patterns of pAS immunoreactivity were variable. Delicate and tortuous perivascular nerve fibers were identified in the interlobular connective tissue in most of the positive cases. Small nerves also showed diffuse immunoreactivity along axons (Figure 3, D and F) . In few cases, tiny periglandular nerve fibers were identified ( Figure 3E, upper panel) . Coarse aggregates were rarely observed. This pattern was comparable when using the 5G4 antibody ( Figure 3E, lower panel) . Double immunofluorescence labeling showed a distribution of both tiny and coarser pAS aggregates within PGP-positive nerve fibers. Lewy body-type deposits were not identified, but these were not expected as no autonomic ganglia were present in the biopsies. Negative cases showed no immunoreactivity signal. In all cases examined, anti-TH immunohistochemistry revealed very tiny and delicate fibers around glandular structures but mostly around small-and middle-sized vessels. Some cases showed a higher density of fibers than others, generally depending on the variable number of vessels and connective tissue. Overall, we found no good correlation between the semiquantitative density of TH-positive fibers and the presence of pAS aggregates. This was also not observed when analyzing the different study groups separately (Table 2) .
Thirty-one participants with IRBD with pAS immunoreactivity showed no differences with the 31 individuals in whom pAS deposits were not detected regarding age at biopsy (p = 0.272), gender (p = 0.119), interval between IRBD diagnosis and biopsy (p = 0.588), MDS-UPDRS-III score (p = 0.676), constipation (p = 0.799), depression (p = 0.607), UPSIT-40 score (p = 0.565), substantia nigra echogenic size (p = 0.172), and number of salivary glands screened (p = 0.869). Table 3 summarizes the presence of pAS in 15 of the 62 patients with IRBD included in the present study who previously underwent colonic or submandibular gland biopsies. The mean interval between colonic biopsy and labial biopsy was 2.6 ± 0.3 (range, 2.0 to 2.9) years, and between submandibular gland biopsy and labial biopsy was of 1.0 ± 0.5 (range, 0.6 to 2.0) years. Five patients showed pAS immunopositivity in the submandibular gland or in the colon but not in the labial minor salivary glands. Two patients had immunoreactivity in the labial salivary glands but not in the colon. Conversely, two patients had immunoreactivity in colon but not in the labial salivary glands. After 1.7 ± 0.3 years of follow-up from biopsy, 8 of 31 (25.8%) pAS positives phenoconverted (7 to PD and 1 to DLB), and 5 of 31 (16.1%) pAS negatives phenoconverted (all 5 to PD).
Seven participants with PD in whom labial pAS aggregates were identified showed no statistical differences with the six patients with PD without pAS deposits regarding age at biopsy (p = 0. *Clinical status assessed 1.7 ± 0.3 years after minor salivary glands biopsy; ND = not done.
The mean interval between colonic biopsy and labial biopsy was of 2.6 ± 0.3 years, and between submandibular gland biopsy and labial biopsy was of 1.0 ± 0.5 years.
Five participants with DLB who had pAS accumulation showed no statistical differences with the five patients with DLB without pAS regarding age at biopsy (p = 0.480), gender (p = 0.292), interval between IRBD diagnosis and DLB diagnosis (p = 0.606), interval between DLB diagnosis and biopsy (p = 0.537), interval between diagnosis of IRBD and biopsy (p = 0.497), MDS-UPDRS-III score (p = 0.823), Hoehn and Yahr stage (p = 0.194), and number of salivary glands analyzed (p = 0.548).
Aggregates of pAS were detected in only one control. This individual was a 70-year-old man with obstructive sleep apnea syndrome. He was a nonsmoker, noncaffeine user, had documented asymptomatic orthostatic hypotension, and 123 I-FP-CIT DAT-SPECT showed reduced dopamine transporter uptake in the right putamen. He had no environment or familial risk factors of PD, showed normal neurological examination with MDS-UPDRS-III score of 2 points, preserved smell function (UPSIT-40 score of 23 points, when normal values in our setting are a score higher than 18) [22] , absence of constipation and depression, normal Mini-Mental State Examination score of 26 points, no excessive daytime somnolence (Epworth Sleepiness scale score of 6 points), no erectile or urine dysfunction, and lack of RBD demonstrated by video-polysomnography. In this participant, the likelihood ratio for prodromal PD was 28% [27] .
Safety of the procedure
No complications occurred during the biopsy. Reported adverse events occurring within the week after biopsy were lip bruising (9.2%), swelling (6.6%), pain (2.4%), and numbness (1.7%). In all the instances, these adverse events were mild, transient, and did not require treatment.
Discussion
In the study reported here, labial minor salivary gland biopsy proved to be a safe procedure that allows detection of pAS accumulation in the peripheral autonomic nervous system in participants with IRBD. In agreement with previous studies performed in living IRBD individuals who underwent biopsies of the colon [7] , submandibular gland [8] , and skin [9, 10] , the present work supports the concept that IRBD represents a synucleinopathy.
There are about 100 minor salivary glands, ranging in size from 1 to 3 mm that are located superficially within the submucosa of the inner side of the lips [32] . The labial minor salivary glands constitute an attractive target for the detection of pAS as they receive autonomic innervation and are easily accessible by a safe and simple biopsy procedure that is routinely performed for diagnostic purposes [33] .
Previous studies in IRBD have shown that colonic, submandibular, and skin biopsies are procedures with moderate sensitivity to identify pAS and with very high specificity to distinguish patients from controls [7] [8] [9] [10] . According to available published data and our current work, it is difficult to establish which is the optimal site to detect abnormal pAS in IRBD. In the only study where colonic biopsy was performed, sufficient biopsy material in the submucosa was available in 17 of 20 (85%) participants with IRBD and pAS was seen in only four of these 17 (sensitivity of 23.5%) [7] . Biopsy of the skin is a minimally invasive technique with minor discomfort for the patient and obtains adequate dermal tissue in most of the cases. In IRBD, the sensitivity of skin biopsy to detect pAS accumulation is higher than in the colon (56%-75%), but it is uncertain which region in the skin offers the highest sensitivity to detect pAS, and how many regions are needed to be biopsied to obtain a high sensitivity [9, 10] . In IRBD, biopsy of the submandibular gland shows the highest sensitivity (89%) to detect pAS but is limited by the fact that the procedure may not obtain gland parenchyma in about 50 per cent of individuals. Technical refinement of the biopsy is needed to improve the accuracy to obtain submandibular gland parenchyma. In comparison with submandibular gland biopsy, labial minor salivary glands biopsy obtains sufficient gland tissue for adequate study in all instances (100%) but the sensitivity to detect pAS is lower (50%). In our current study, in four patients with IRBD, pAS positivity was detected in the submandibular gland but not in the minor salivary glands ( Table 2 ). Submandibular and minor salivary gland biopsies have similar invasiveness and both are safe procedures associated with minor and transient local side effects. Taken together, more optimal and sensitive approaches are still needed to improve the accuracy for detecting abnormal pAS in peripheral tissues in participants with IRBD. They may include (1) development of more refined and sensitive techniques to detect pathological forms of pAS [34] , (2) searching other anatomical accessible sites for pathological forms of α-synuclein, and (3) carrying biopsies in multiple peripheral organs within the same participant at a single time point [35, 36] .
We detected pAS aggregates in 50 per cent of the patients with IRBD. Compared with those with pAS negativity, participants with IRBD with pAS positivity were not older and seemed not to be affected by a more advanced stage of the process since RBD duration was not longer, motor abnormalities were not detectable, and the frequency of some markers of neurodegeneration (constipation, depression, hyposmia, and substantia nigra hyperechogenicity) was similar between both groups. It is possible that the minor salivary glands of these negative patients contained pAS deposits that were not detectable by the methodology applied (e.g. insufficient number of glands or sections analyzed, immunohistochemical methods, or the antibodies used could miss other forms of pathological α-synuclein). Still we performed serial sections of the whole gland to include the maximal tissue as possible, performed repeated immunohistochemical stains, and applied in all cases two different antibodies, one against pAS at serine 129 and the other one (5G4) against conformational altered α-synuclein aggregates, including disease-associated oligomeric forms but not physiological monomeric forms. Alternatively, it is also possible that pAS deposits were not present in some of our patients because small autonomic fibers were abnormally reduced in the salivary glands, as cutaneous denervation has been described in the skin in IRBD [37] . However, semiquantitative assessment of TH-positive fiber density did not reveal a good correlation between fiber density and pAS-positive or pAS-negative participants and also not within the different study groups.
Accumulation of pAS was not detected in 46 per cent of our patients with PD. It has been suggested that absence of pAS aggregates in participants with PD may be explained by loss of autonomic nerve fibers within the glands [38] or by methodologic factors as discussed above in IRBD. But again, semiquantitative assessment of TH-positive fiber density did not show differences between pAS-positive and pAS-negative patients with PD, although none of them had "abundant" fibers. We are not aware of studies that have examined the presence of pAS in the labial minor salivary glands of postmortem or living participants with DLB. In our study, pAS deposits in living patients with DLB were found in a similar proportion as in PD in the salivary glands, as recently described in the skin [39, 40] . Our results suggest that detection of pAS in labial minor salivary gland tissue may serve for histological confirmation in individuals clinically diagnosed with probable PD and DLB. Of note, in manifested PD, some studies have shown that skin biopsy is less invasive and more sensitive to detect pAS than labial salivar biopsy [12, 41, 42, 43] .
We found that pAS aggregates were detected in one of our 33 controls. This individual, carefully evaluated, showed reduced dopamine transporter uptake in the putamen. Incidental pAS deposits in the peripheral nervous system of living individuals without neurological diseases are not exceptional [13, [43] [44] [45] [46] . These cases may not represent false positive cases but likely "incidental or preclinical" cases, given that postmortem studies in the brain show Lewy body pathology in about 10%-20% of individuals older than 60 years without parkinsonism or dementia during life [47] . It remains to be established whether incidental pAS in the peripheral nervous system represents prodromal Lewy body disorder.
A limitation of our study was the relatively small sample size of patients with IRBD evaluated. Another limitation is the relatively small number of glands analyzed given that there are about 100 minor salivary glands in the lips [33] . We examined a mean of 5.5 glands, which is the standard number routinely screened for the diagnosis of Sjögren syndrome and other systemic and local conditions. It is possible that if we had removed more glands, we would have found more positive pAS cases, but this would have required more invasive surgery and increasing the rate and severity of adverse events. Clinical follow-up after biopsy was short to assess if detectable pAS in the minor salivary glands of patients with IRBD is an indicator of early phenoconversion to clinically manifested PD and DLB.
In summary, our study shows that labial minor salivary glands biopsy is a minimally invasive procedure causing only minor and transient side effects which is useful to detect pAS deposits in participants with IRBD. The biopsy may also be useful for histological confirmation in participants clinically diagnosed with PD and DLB. The applicability of this biopsy in clinical practice and in the design of neuroprotective trials in IRBD requires further investigation.
